Pre-Made Anakinra Biosimilar, Recombinant Protein targeting IL1R1: Recombinant therapeutic protein targeting CD121A/D2S1473/IL-1R-alpha/IL1R/IL1RA/P80 for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-732

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-732 Category Tag

Product Details

Pre-Made Anakinra Biosimilar, Recombinant Protein targeting IL1R1: Recombinant therapeutic protein targeting CD121A/D2S1473/IL-1R-alpha/IL1R/IL1RA/P80 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Anakinra, sold under the brand name Kineret, is a biopharmaceutical medication used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still’s disease.[3] It is a recombinant and slightly modified version of the human interleukin 1 receptor antagonist protein.[3] It is marketed by Swedish Orphan Biovitrum.[1] Anakinra is administered by subcutaneous injection.[2]

Anakinra is used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still’s disease. Anakinra is a recombinant, non-glycosylated human interleukin-1 receptor antagonist (IL-1Ra). The anakinra has an extra methionine residue at the amino terminus compared to the native human IL-1Ra. Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.

Products Name (INN Index)

Pre-Made Anakinra Biosimilar, Recombinant Protein targeting IL1R1: Recombinant therapeutic protein targeting CD121A/D2S1473/IL-1R-alpha/IL1R/IL1RA/P80 Pre-made [INN Name] Biosimilar, [Format] target

INN Name

anakinra

Target

IL1R1

Format

Recombinant Protein

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IL1RN (interleukin 1 receptor antagonist, IL1RA, IL-1RN, "interleukin-1 receptor antagonist protein") recombinant, non glycosylated

VD LC

IL1RN (interleukin 1 receptor antagonist, IL1RA, IL-1RN, "interleukin-1 receptor antagonist protein") recombinant, non glycosylated

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Amgen (Thousand Oaks CA USA) / BioVitrum (Saint- Petersburg Russia)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IL1R1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide